Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care.

Jordan E TuiaTimothée OlivierVinay K Prasad

Published in: American journal of clinical oncology (2022)

Trials for adjuvant trastuzumab did not disambiguate between crossover (1) in the adjuvant setting or (2) at recurrence. Due to the low reported rate of crossover, it is questionable if participants received the standard of care.

Keyphrases

early stage
open label
double blind
placebo controlled
epidermal growth factor receptor
healthcare
palliative care
metastatic breast cancer
oxidative stress
clinical trial
randomized controlled trial
robot assisted
chronic pain
study protocol
tyrosine kinase
free survival